Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
1 other identifier
observational
150
0 countries
N/A
Brief Summary
The investigators aim to compare the clinical characteristics and outcomes of SLE between male and female Egyptian patients at Assuit University Hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2020
CompletedFirst Posted
Study publicly available on registry
January 21, 2020
CompletedStudy Start
First participant enrolled
March 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedJanuary 21, 2020
January 1, 2020
2 years
January 11, 2020
January 16, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Presentation, complication, and mortality among males and female patients with SLE
Using percentages, we will track the number of patients that develop certain clinical conditions (such as arthritis, malar rash, .... ), complications (such as nephritis), and mortality rates. These numbers and percentages will be used to compare males with females (incidence rates for each event will be calculated).
2 years
Study Arms (1)
SLE patients
Any SLE patients between 18 and 40 years old.
Eligibility Criteria
Any SLE patients between 18and 40 years old will be eligible to be included in our study.
You may qualify if:
- Any SLE patients between 18and 40 years old will be eligible to be included in our study.
You may not qualify if:
- Patients below the age of 18 or above 40.
- Any other autoimmune disease.
- Cardiovascular, neurological, renal complications due to other co-morbidity such as DM and HTN.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Mok CC, Lau CS, Chan TM, Wong RW. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus. 1999;8(3):188-96. doi: 10.1191/096120399678847605.
PMID: 10342711RESULTSoto ME, Vallejo M, Guillen F, Simon JA, Arena E, Reyes PA. Gender impact in systemic lupus erythematosus. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):713-21.
PMID: 15638045RESULTEl Hadidi KT, Medhat BM, Abdel Baki NM, Abdel Kafy H, Abdelrahaman W, Yousri AY, Attia DH, Eissa M, El Dessouki D, Elgazzar I, Elgengehy FT, El Ghobashy N, El Hadary H, El Mardenly G, El Naggar H, El Nahas AM, El Refai RM, El Rwiny HA, Elsman RM, Galal M, Ghoniem S, Maged LA, Sally SM, Naji H, Saad S, Shaaban M, Sharaf M, Sobhy N, Soliman RM, El Hadidi TS. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus. 2018 May;27(6):1030-1038. doi: 10.1177/0961203317751856. Epub 2018 Feb 10.
PMID: 29431056RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Ahmed Aeltaih, MBBch
Assuit University Hospitals
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 11, 2020
First Posted
January 21, 2020
Study Start
March 1, 2020
Primary Completion
March 1, 2022
Study Completion
March 1, 2022
Last Updated
January 21, 2020
Record last verified: 2020-01